388 related articles for article (PubMed ID: 17386412)
1. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
2. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
[TBL] [Abstract][Full Text] [Related]
3. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.
Li B; Zhang R; Li J; Zhang L; Ding G; Luo P; He S; Dong Y; Jiang W; Lu Y; Cao H; Zheng J; Zhou H
Int Immunopharmacol; 2008 Mar; 8(3):379-89. PubMed ID: 18279792
[TBL] [Abstract][Full Text] [Related]
4. Decreased intracellular TLR9 confers hyporesponsiveness of RAW264.7 cells to subsequent CpG ODN challenge.
Wei L; Hong Z; Jiang Z; Guofu D; Hongwei C; Liangxi W; Yongling L; Bin L; Ping L
Int Immunopharmacol; 2006 Jun; 6(6):935-46. PubMed ID: 16644479
[TBL] [Abstract][Full Text] [Related]
5. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
6. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
7. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation.
Li B; Li J; Pan X; Ding G; Cao H; Jiang W; Zheng J; Zhou H
Int Immunopharmacol; 2010 Mar; 10(3):344-50. PubMed ID: 20005985
[TBL] [Abstract][Full Text] [Related]
8. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs.
Li Y; Cao H; Wang N; Xiang Y; Lu Y; Zhao K; Zheng J; Zhou H
Vaccine; 2011 Mar; 29(11):2193-8. PubMed ID: 21036131
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotides protect mice from lethal challenge with Candida albicans via a pathway involving tumor necrosis factor-alpha-dependent interleukin-12 induction.
Choi JH; Ko HM; Park SJ; Kim KJ; Kim SH; Im SY
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):155-62. PubMed ID: 17854477
[TBL] [Abstract][Full Text] [Related]
10. Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling.
Lim EJ; Lee SH; Lee JG; Chin BR; Bae YS; Kim JR; Lee CH; Baek SH
FEBS Lett; 2006 Aug; 580(18):4533-8. PubMed ID: 16870179
[TBL] [Abstract][Full Text] [Related]
11. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
12. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
15. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA.
Suzuki K; Suda T; Naito T; Ide K; Chida K; Nakamura H
Am J Respir Crit Care Med; 2005 Apr; 171(7):707-13. PubMed ID: 15640365
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 mediates CpG-DNA signaling.
Chuang TH; Lee J; Kline L; Mathison JC; Ulevitch RJ
J Leukoc Biol; 2002 Mar; 71(3):538-44. PubMed ID: 11867692
[TBL] [Abstract][Full Text] [Related]
17. Targeting CpG DNA to screen and isolate anti-sepsis fraction and monomers from traditional Chinese herbs using affinity biosensor technology.
Liu X; Cheng J; Zheng X; Chen Y; Wu C; Li B; Fu J; Cao H; Lu Y; Li J; Zheng J; Zhou H
Int Immunopharmacol; 2009 Aug; 9(9):1021-31. PubMed ID: 19376273
[TBL] [Abstract][Full Text] [Related]
18. Discrepant roles of CpG ODN on acute alcohol-induced liver injury in mice.
Wang Z; Wu X; Zhang Y; Zhou L; Li L; Yu Y; Wang L
Int Immunopharmacol; 2012 Mar; 12(3):526-33. PubMed ID: 22293535
[TBL] [Abstract][Full Text] [Related]
19. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
[TBL] [Abstract][Full Text] [Related]
20. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways.
Yasuda K; Ogawa Y; Yamane I; Nishikawa M; Takakura Y
J Leukoc Biol; 2005 Jan; 77(1):71-9. PubMed ID: 15496451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
